Is there currently a domestic version of adagrasib (Krazati) and an introduction to the progress of localization

Adagrasiib (Krazati) is a KRAS G12C inhibitor, similar to sotorasiib, and is mainly targeted at patients with non-small cell lung cancer and some gastrointestinal tumors with KRAS G12C mutations. The drug was developed by Mirati Therapeutics of the United States and received accelerated approval from the FDA at the end of 2022. Its mechanism of action lies in precisely inhibiting the KRAS G12C mutated protein, thereby blocking the signaling pathways of tumor cells, and has strong clinical application potential.

At present, adagrasib has not been approved for marketing in China, and domestic patients cannot purchase it directly through regular hospital pharmacies. As for the progress of localization, some domestic pharmaceutical companies have announced the launch of research and development of KRAS G12C inhibitors, but most are still in the early clinical stages and cannot replace imported drugs in the short term. Therefore, there is currently no domestic version of adagrasib, and patients can only rely on overseas channels if they need medication.

In overseas markets, the U.S. original drug of adagrasib is expensive, with the price of each box being as high as hundreds of thousands of yuan, which is a heavy burden for most patients. In contrast, some countries already have generic versions of adagrasib, such as the version produced in Laos. The ingredients of Lao generic drugs are basically the same as those of the original drugs, but the price is greatly reduced. The current market price is about more than 3,000 yuan per box, providing patients with a more economical choice.

For domestic patients, adagrasib can only be obtained through formal overseas channels and used rationally under the guidance of a doctor. When choosing generic drugs, you need to pay attention to the source and quality of the drugs to avoid risks caused by unknown channels. Looking to the future, with the continuous research and development of domestic pharmaceutical companies in the field of KRAS G12C targeted drugs, it is expected that domestic alternative drugs will appear in the next few years. By then, patients will not only enjoy more convenient drug purchase channels, but also may have their financial burden significantly reduced due to medical insurance coverage.

Reference link:https://www.drugs.com